SBIR Awarded $2.1 Million Maas BiolAB, LLC for Cyclosporin ALS Treatment

Published: Oct 11, 2007

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Maas BiolAB received a Small Business Innovation Research (SBIR) grant of $2.1 million over three years from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for the translational project “Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis (ALS).”

Back to news